Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Petra Kövy, Nóra Meggyesi, Lívia Varga, Katalin Balassa, András Bors, László Gopcsa, Melinda Paksi, Árpád Bátai, Eszter Vad, János Sinkó, Attila Tordai, Tamás Masszi, Péter Reményi, Hajnalka Andrikovics

Research output: Article

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of TGFB1 gene −1347C>T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. TGFB1 variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor TGFB1 genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8%; CT: 46.8 ± 4.8%; TT: 35.6 ± 9.3%; p = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95%CI:1.35–4.10, p = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10%; CT:17%; TT:24%], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24%; CT:26%; TT:46%, p = 0.035). We did not find any association between recipient TGFB1 −1347C>T polymorphism and HSCT outcome. Our results suggest that donor TGFB1 −1347C>T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusAccepted/In press - jan. 1 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Biomarkers
Transplantation Conditioning
Transforming Growth Factors
Multivariate Analysis
Genotype
Cytokines
Mortality
DNA
Incidence
Infection
Genes
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. / Kövy, Petra; Meggyesi, Nóra; Varga, Lívia; Balassa, Katalin; Bors, András; Gopcsa, László; Paksi, Melinda; Bátai, Árpád; Vad, Eszter; Sinkó, János; Tordai, Attila; Masszi, Tamás; Reményi, Péter; Andrikovics, Hajnalka.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Article

Kövy, Petra ; Meggyesi, Nóra ; Varga, Lívia ; Balassa, Katalin ; Bors, András ; Gopcsa, László ; Paksi, Melinda ; Bátai, Árpád ; Vad, Eszter ; Sinkó, János ; Tordai, Attila ; Masszi, Tamás ; Reményi, Péter ; Andrikovics, Hajnalka. / Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. In: Bone Marrow Transplantation. 2019.
@article{57a61239c8da41389238e5a09abe3959,
title = "Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of TGFB1 gene −1347C>T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. TGFB1 variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor TGFB1 genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8{\%}; CT: 46.8 ± 4.8{\%}; TT: 35.6 ± 9.3{\%}; p = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95{\%}CI:1.35–4.10, p = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10{\%}; CT:17{\%}; TT:24{\%}], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24{\%}; CT:26{\%}; TT:46{\%}, p = 0.035). We did not find any association between recipient TGFB1 −1347C>T polymorphism and HSCT outcome. Our results suggest that donor TGFB1 −1347C>T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.",
author = "Petra K{\"o}vy and N{\'o}ra Meggyesi and L{\'i}via Varga and Katalin Balassa and Andr{\'a}s Bors and L{\'a}szl{\'o} Gopcsa and Melinda Paksi and {\'A}rp{\'a}d B{\'a}tai and Eszter Vad and J{\'a}nos Sink{\'o} and Attila Tordai and Tam{\'a}s Masszi and P{\'e}ter Rem{\'e}nyi and Hajnalka Andrikovics",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0656-4",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

AU - Kövy, Petra

AU - Meggyesi, Nóra

AU - Varga, Lívia

AU - Balassa, Katalin

AU - Bors, András

AU - Gopcsa, László

AU - Paksi, Melinda

AU - Bátai, Árpád

AU - Vad, Eszter

AU - Sinkó, János

AU - Tordai, Attila

AU - Masszi, Tamás

AU - Reményi, Péter

AU - Andrikovics, Hajnalka

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of TGFB1 gene −1347C>T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. TGFB1 variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor TGFB1 genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8%; CT: 46.8 ± 4.8%; TT: 35.6 ± 9.3%; p = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95%CI:1.35–4.10, p = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10%; CT:17%; TT:24%], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24%; CT:26%; TT:46%, p = 0.035). We did not find any association between recipient TGFB1 −1347C>T polymorphism and HSCT outcome. Our results suggest that donor TGFB1 −1347C>T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of TGFB1 gene −1347C>T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. TGFB1 variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor TGFB1 genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8%; CT: 46.8 ± 4.8%; TT: 35.6 ± 9.3%; p = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95%CI:1.35–4.10, p = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10%; CT:17%; TT:24%], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24%; CT:26%; TT:46%, p = 0.035). We did not find any association between recipient TGFB1 −1347C>T polymorphism and HSCT outcome. Our results suggest that donor TGFB1 −1347C>T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85073832137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073832137&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0656-4

DO - 10.1038/s41409-019-0656-4

M3 - Article

C2 - 31527815

AN - SCOPUS:85073832137

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -